Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENDIPITY: Permixon for chronic prostate inflammation in BPH
2025-525123-27-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) and prostatitis comparing Permixon with Placebo (2 arms). Primary endpoint: Proportion of patients undergoing a repeat prostate biopsy within 12 months. Planned start Jun 2026; status: authorised.
02
Drugs
saw palmetto fruit extract
03
Conditions
benign prostatic hyperplasia (BPH)prostatitis
Beyond the preview
Go deeper on 2025-525123-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525123-27-00.